Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.36 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 2/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | GNPAT | O15228 | 1/20 | 0.35 |
| ▸ | OTC | P00480 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27532875 | 1.00 | FOLH1 (0.41) | FOLH1ALOX15SMN1; SMN2MEN1CYP1A2 | |
| SCHEMBL117141 | 0.95 | C3AR1 (0.40) | FOLH1ALOX15SMN1; SMN2MEN1CYP1A2 | |
| SCHEMBL8164682 | 0.95 | C3AR1 (0.40) | FOLH1ALOX15SMN1; SMN2MEN1CYP1A2 | |
| SCHEMBL466294 | 0.95 | C3AR1 (0.40) | FOLH1ALOX15SMN1; SMN2MEN1CYP1A2 | |
| Acetic Acid SCHEMBL2304560 | 0.90 | FOLH1 (0.39) | FOLH1ALOX15SMN1; SMN2MEN1CYP1A2 | |
| SCHEMBL30516542 | 0.87 | TGFBR1 (0.33) | FOLH1ALOX15SMN1; SMN2MEN1CYP1A2 | |
| SCHEMBL8662167 | 0.86 | GNPAT (0.45) | FOLH1ALOX15SMN1; SMN2MEN1CYP1A2 | |
| SCHEMBL8663718 | 0.86 | GNPAT (0.45) | FOLH1ALOX15SMN1; SMN2MEN1CYP1A2 | |
| SCHEMBL25342849 | 0.86 | C3AR1 (0.47) | FOLH1SMN1; SMN2MEN1KMT2ANOD1 | |
| SCHEMBL8663352 | 0.85 | FOLH1 (0.43) | FOLH1ALOX15SMN1; SMN2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060009431-A1 | Nitrosated and nitrosylated compounds, compositions and methods use | NITROMED, INC. (US) | 2006-01-12 | — | — | US | claimed |
| EP-1603933-A2 | NITROSATED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-12-14 | — | — | EP | claimed |
| WO-2004098538-A2 | NITROSATED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-11-18 | — | — | WO | claimed |
| EP-1077692-B1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2004-07-28 | — | — | EP | claimed |
| WO-2002017898-A2 | COMPOSITIONS AND METHODS FOR INDUCING VASORELAXATION | SACKS MEIR S (US) | 2002-03-07 | — | — | WO | claimed |
| EP-1077692-A1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | Warner-Lambert Company LLC (US) | 2001-02-28 | — | — | EP | claimed |
| WO-1999059573-A1 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER-LAMBERT COMPANY (US) | 1999-11-25 | — | — | WO | claimed |
| US-12383522-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | AMNEAL PHARMACEUTICALS LLC (US) | 2025-08-12 | — | — | US | disclosed |
| US-11931328-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | AMNEAL PHARMACEUTICALS LLC (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240082193-A1 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | AMNEAL PHARMACEUTICALS LLC (US) | 2024-03-14 | — | — | US | disclosed |
| WO-2024010854-A1 | RAPID GENERATION OF BREATH-BASED HEALTH REPORTS AND SYSTEMS FOR USE IN THE SAME | DIAGNOSE EARLY, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-11850225-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | AMNEAL PHARMACEUTICALS LLC (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230218554-A1 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | AMNEAL PHARMACEUTICALS LLC (US) | 2023-07-13 | — | — | US | disclosed |
| EP-1351674-A1 | PHARMACOTHERAPY FOR VASCULAR DYSFUNCTION ASSOCIATED WITH DEFICIENT NITRIC OXIDE BIOACTIVITY | CORNELL RESEARCH FOUNDATION, INC. (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20030073747-A1 | Reversing or preventing premature vascular senescence | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-04-17 | — | — | US | disclosed |
| WO-2002017898-A2 | COMPOSITIONS AND METHODS FOR INDUCING VASORELAXATION | SACKS MEIR S (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2001078717-A1 | PHARMACOTHERAPY FOR VASCULAR DYSFUNCTION ASSOCIATED WITH DEFICIENT NITRIC OXIDE BIOACTIVITY | CORNELL RESEARCH FOUNDATION, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
| EP-1140854-A2 | METHODS FOR THE SYNTHESIS OF ALPHA-HYDROXY-BETA-AMINO ACID AND AMIDE DERIVATIVES | CORVAS INTERNATIONAL, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035868-A2 | METHODS FOR THE SYNTHESIS OF ALPHA-HYDROXY-BETA-AMINO ACID AND AMIDE DERIVATIVES | CORVAS INTERNATIONAL, INC. (US) | 2000-06-22 | — | — | WO | disclosed |
| EP-0413528-A1 | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use | Yu, Ruey J., Dr. (US) | 1991-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240082193-A1 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | GABRB1, GABRB2, GABBR1 | FOLH1 762/4885ALOX15 960/4885SMN1; SMN2 32/4885 |
| US-12383522-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | GABRB1, GABRB2, GABBR1 | FOLH1 762/4885ALOX15 960/4885SMN1; SMN2 32/4885 |
| US-20060009431-A1 | Nitrosated and nitrosylated compounds, compositions and methods use | TBXA2R, TXNRD3, NOS3 | FOLH1 4849/4885ALOX15 120/4885SMN1; SMN2 2553/4885 |
| US-11931328-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | GABRA6, GABBR1, GABBR2 | FOLH1 3325/4885ALOX15 857/4885SMN1; SMN2 54/4885 |
| US-20030073747-A1 | Reversing or preventing premature vascular senescence | AGER, GLA, POT1 | FOLH1 2744/4885ALOX15 1264/4885SMN1; SMN2 1990/4885 |
| US-11850225-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | GABRB1, GABRB2, GABBR1 | FOLH1 722/4885ALOX15 963/4885SMN1; SMN2 35/4885 |
| US-20230218554-A1 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | GABRA6, GABBR1, GABBR2 | FOLH1 3325/4885ALOX15 857/4885SMN1; SMN2 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.